Is preclinical data sharing the new norm?

Is preclinical data sharing the new norm? Drug Discovery Today Volume 23, Number 3 March 2018 PERSPECTIVE feature Is preclinical data sharing the new norm? Katharine A. Briggs Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the benefits of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the benefits and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing. Introduction Reasons for data sharing health research and aims to increase the avail- In this article, I look at the benefits and risks Benefits to public health ability and use of health research data in ways associated with sharing preclinical data. The Approximately 35% of all drug development that are equitable, ethical, and efficient (http:// projects fail as a result of toxicity detected during proprietary nature of these data means that grants.nih.gov/grants/policy/data_sharing/; preclinical safety studies [2]. Therefore, animal initiatives to share these data tend to be restricted www.mrc.ac.uk/research/research-policy-ethics/ studies are an important safeguard for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Discovery Today Elsevier

Is preclinical data sharing the new norm?

Briggs, Katharine A.
Drug Discovery Today, Volume 23 (3) – Mar 1, 2018
4 pages
Read Article

Loading next page...
 
/lp/elsevier/is-preclinical-data-sharing-the-new-norm-XmkER0mdbs
Publisher
Elsevier
Copyright
Copyright © 2016 Elsevier Ltd
ISSN
1359-6446
DOI
10.1016/j.drudis.2016.05.003
Publisher site
See Article on Publisher Site

Abstract

Drug Discovery Today Volume 23, Number 3 March 2018 PERSPECTIVE feature Is preclinical data sharing the new norm? Katharine A. Briggs Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the benefits of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the benefits and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing. Introduction Reasons for data sharing health research and aims to increase the avail- In this article, I look at the benefits and risks Benefits to public health ability and use of health research data in ways associated with sharing preclinical data. The Approximately 35% of all drug development that are equitable, ethical, and efficient (http:// projects fail as a result of toxicity detected during proprietary nature of these data means that grants.nih.gov/grants/policy/data_sharing/; preclinical safety studies [2]. Therefore, animal initiatives to share these data tend to be restricted www.mrc.ac.uk/research/research-policy-ethics/ studies are an important safeguard for

Journal

Drug Discovery Today – Elsevier

Published: Mar 1, 2018

References

  • Report UKeS-2006-02: Large-Scale Data Sharing in the Life Sciences: Data Standards, Incentives, Barriers and Funding Models (The ‘Joint Data Standards Study’)
    Lord, P.
  • Handing over the baton: connecting medicinal chemistry with process R&D
    Federsel, H.J.
  • Sharing research data to improve public health
    Walport, M.; Brest, P.
  • Principles and Guidelines for Reporting Preclinical Research
    NIH
  • Working with the Pharmaceutical Industry 2004–2014: Pioneering Better Science
    NC3Rs
  • Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials
    Sewell, F.
  • In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic
    Marchant, C.A.
  • Progress in sharing data from repeated dose toxicity studies
    Williamson, E.; Briggs, K.
  • The Lhasa Limited Vitic Excipient (vehicle) Database: an information source on vehicle tolerability in rabbits
    Powles-Glover, N.S.; Edwards, J.M.
  • Excipients data sharing initiative: a step towards 3-R principle implementation
    Werner, A.-L.
  • Utilising knowledge relating to 5α-reductase inhibition in the prediction of teratogenicity
    Cayley, A.
  • Identification of adverse outcome pathways for the nephrotoxicity of nucleoside and nucleotide anti-viral drugs
    Drewe, W.C.
  • Using adverse outcome pathways to highlight existing knowledge for mechanisms of teratogenicity resulting from endocrine disruption
    Patel, M.L.
  • Developing existing in vitro structural alerts for chromosome damage in order to predict in vivo activity and help direct future testing
    Canipa, S.
  • The Sociology of Science – Theoretical and Empirical Investigations
    Merton, R.K.
  • The use of in-silico tools and data sharing to reduce toxicity testing of impurities
    Dodd, A.; Fielding, K.
  • Workshop 12: mechanistic approaches to understanding drug induced liver injury: IMI's MIP-DILI project, presented at Eurotox 2014
    Weaver, R.
  • Boronic acids – a novel class of bacterial mutagen
    O’Donovan, M.R.
  • Investigating a relationship between the mutagenicity of arylboronic acids and 11B NMR chemical shifts
    Pellizzaro, M.L.
  • Access vs. Importance – A Global Study Assessing the Importance of and Ease of Access to Professional and Academic Information, Phase I Results
    Publishing Research Consortium
  • Inroads to predict in vivo toxicology: an introduction to the eTOX project
    Briggs, K.
  • REPDOSE: a database on repeated dose toxicity studies of commercial chemicals: a multifunctional tool
    Bitsch, A.
  • The cost of creating a new drug now $5 billion, pushing big pharma to change
    Herper, M.
  • Identifying Benefits Arising from the Curation and Open Sharing of Research Data Produced by UK Higher Education and Research Institutes
    Fry, J.
  • Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery
    Hohman, M.
  • Data sharing by scientists: practices and perceptions
    Tenopir, C.
  • ToxML: a structured and serialisable exchange standard for toxicology
    Ali, M.A.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial